Shilin, meaning forest of knowledge in Chinese, is a subscription knowledgebase of government regulations and policies, and industry practices for pharmaceutical products, covering China, the United States, the European Union and other regions. The Shilin content is linked in a Wikipedia style via embedded hyperlinks, and is updated daily.

The Shilin Newsletter is a greatly simplified version of Shilin, providing weekly update of the government regulations and policies on the pharmaceutical industry in China. All updates and feature articles, along with the Chinese Pharmacopeia (ChP) are archived and indexed, and their content is hyperlinked via keywords to varying degrees.

Who are Shilin customers?

Over 160 subscribers include:

Regulators: Center for Drug Evaluation (CDE) and Center for Food and Drug Inspection (CFDI) of China's National Medical Products Administration (NMPA), and their counterparts of major provincial medical products agencies of Beijing, Shanghai, Guangdong, Shandong, Jiangsu, Sichuan and etc.
The US Food and Drug Administration (FDA) China Office.
Domestic pharmaceutical and service companies: Hengrui, Qilu, China National Biotec Group, BeiGene, Hepalink, Innovent, Wuxi, and etc.
Multi-national pharmaceutical companies in China: Lilly, Pfizer, Merck, J&J, Roche, Novartis, Bayer, Boehringer Ingelheim, and etc.

Contact Information

Phone: +86 10-6254-2532

Email: newsletter@shilinx.com

登录